Theranexus SA

NEW
XPAR:ALTHX (France)  
€ 0.43 +0.025 (+6.1%) Mar 25
At Loss
P/B:
1.58
Market Cap:
€ 3.51M ($ 3.78M)
Enterprise V:
€ 4.70M ($ 5.05M)
Volume:
51.70K
Avg Vol (2M):
40.22K
Trade In:
What is a stock summary page? Click here for an overview.

Business Description

Description
Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.
Name Current Vs Industry Vs History
Cash-To-Debt 0.6
Debt-to-Equity -978.67
Debt-to-EBITDA -0.78
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.45
Quick Ratio 2.45
Cash Ratio 1.41
Days Payable 101.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -24.4
Shareholder Yield % 30.46
Name Current Vs Industry Vs History
ROE % -190.34
ROA % -47.46
ROIC % -204.55
3-Year ROIIC % 51.02
ROC (Joel Greenblatt) % -1539.63
ROCE % -74.01

GF Value Rank

Name Current Vs Industry Vs History
PB Ratio 1.58
EV-to-EBIT -1.21
EV-to-EBITDA -1.26
EV-to-FCF -0.99
Earnings Yield (Greenblatt) % -82.75
FCF Yield % -138.4

Financials

XPAR:ALTHX's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Theranexus SA Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €)
EPS (TTM) (€) -0.394
Beta 1.09
3-Year Sharpe Ratio -0.55
3-Year Sortino Ratio -0.85
Volatility % 89.68
14-Day RSI 37.12
14-Day ATR (€) 0.025069
20-Day SMA (€) 0.46835
12-1 Month Momentum % -53.41
52-Week Range (€) 0.41 - 1.3
Shares Outstanding (Mil) 8.08

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Theranexus SA Filings

Filing Date Document Date Form
No Filing Data

Theranexus SA Stock Events

Financials Calendars
Event Date Price (€)
No Event Data

Theranexus SA Frequently Asked Questions

What is Theranexus SA(XPAR:ALTHX)'s stock price today?
The current price of XPAR:ALTHX is €0.44. The 52 week high of XPAR:ALTHX is €1.30 and 52 week low is €0.41.
When is next earnings date of Theranexus SA(XPAR:ALTHX)?
The next earnings date of Theranexus SA(XPAR:ALTHX) is .
Does Theranexus SA(XPAR:ALTHX) pay dividends? If so, how much?
Theranexus SA(XPAR:ALTHX) does not pay dividend.

Press Release

Subject Date
No Press Release